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Abstract: Alginates are being increasingly used for cell en-
capsulation and tissue engineering applications; however,
these materials cannot specifically interact with mammalian
cells. We have covalently modified alginates of varying mo-
nomeric ratio with RGD-containing cell adhesion ligands
using carbodiimide chemistry to initiate cell adhesion to
these polymers. We hypothesized that we could control the
function of cells adherent to RGD-modified alginate hydro-
gels by varying alginate polymer type and cell adhesion
ligand density, and we have addressed this possibility by
studying the proliferation and differentiation of C2C12 skel-
etal myoblasts adherent to these materials. RGD density on
alginates of varying monomeric ratio could be controlled
over several orders of magnitude, creating a range of surface
densities from 1–100 fmol/cm2. Myoblast adhesion to these
materials was specific to the RGD ligand, because adhesion
could be competed away with soluble RGD in a dose-
dependent manner. Myoblast proliferation and differentia-
tion could be regulated by varying the alginate monomeric
ratio and the density of RGD ligands at the substrate surface,
and specific combinations of alginate type and RGD density
were required to obtain efficient myoblast differentiation on
these materials. © 2002 John Wiley & Sons, Inc. J Biomed
Mater Res 60: 217–223, 2002
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INTRODUCTION
Biomaterials have recently been required to provide
increasingly sophisticated functions in a variety of ap-
plications, including tissue engineering.1–3 In tissue
engineering, biomaterials are used as scaffolds to
guide the development of new tissues and organs
from transplanted or native cells.2,3 To direct cell and
tissue response, biomaterial design has focused on
controlling the material’s chemistry for promotion of
highly specific binding interactions between the ma-
terial and surrounding cells. This is typically accom-
plished by presentation from the material surface dis-
tinct extracellular matrix or peptide ligands specific to
cell surface receptors, and /or controlling the density,
spatial presentation, or combinations of these ligands
from the material.4–6 The ligand density may regulate
the material’s ability to resist cell-based tractional
forces after adhesion7 and thus mediate changes in cell
morphology. Cell morphology has been clearly dem-
onstrated to correlate with gene expression at a num-
ber of levels.8
Alginates are naturally occurring polysaccharides
that gel in the presence of divalent cations.9 Alginates
are copolymers containing mannuronic acid (M) and
guluronic acid (G) monomeric subunits of varying
amounts and distribution along the polymer back-
bone.9 These subunits differ in their ability to contrib-
ute to hydrogel cross-linking and thus alter the physi-
cal properties of the resultant hydrogels.10 Because of
their gentle gelling properties, alginates are widely
used for cell encapsulation in vitro11 and in vivo12 and
for several tissue engineering applications.13,14 Algi-
nates of varying monomeric ratios (M:G ratio) dem-
onstrate varying biocompatibilities in vivo.15–17 We
have modified alginates of varying M:G ratios with
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RGD-containing peptide sequences18 to obtain cell-
adhesion substrates with controllable chemical and
cell-adhesive properties for model in vitro studies. Un-
like other model cell culture systems, modified algi-
nates translate into in vivo studies quite easily,19–21 and
variables found to control cell function in vitro may be
easily and quickly translated into practical applica-
tions.
Skeletal muscle cells provide a convenient model
cell system to study how biomaterial design variables
may control cell phenotype, because they have bio-
chemically and morphologically distinct proliferative
and differentiated phenotypes.22 Myoblasts main-
tained in high serum medium continuously enter the
cell cycle and proliferate. Myoblasts transferred to low
serum medium (<2% serum) irreversibly exit the cell
cycle, fuse into multinucleated myofibrils, and up-
regulate an entire battery of genes not expressed in the
proliferative phenotype.22 Differentiation-specific
genes include transcription factors (e.g., MyoD, myo-
genin) and functional proteins used in muscle contrac-
tion (e.g., muscle creatine kinase22,23). In the current
studies, we used C2C12 skeletal myoblasts to address
the hypothesis that the ligand density and alginate
chemistry alter cell proliferation and differentiation,
and we demonstrate that specific combinations of ad-
hesion ligands and M:G ratio are required to support
myoblast fusion and differentiation. To the author’s
knowledge, this is the first report that skeletal myo-
blasts are capable of sustained growth and differen-
tiation on highly specific adhesive substrates without
providing whole extracellular matrix (ECM) mol-
ecules such as fibronectin, laminin, or collagen.
MATERIALS AND METHODS
Alginate chemistry
Ultrapure alginates were purchased from ProNova Bio-
medical (Norway), and all chemicals were purchased from
Sigma (St. Louis, MO) unless otherwise stated. MVG algi-
nate, a high G-containing alginate (M:G ratio of 40:60 as
specified by the manufacturer), and MVM alginate, a high
M-containing alginate (M:G ratio of 70:30 as specified by the
manufacturer) were used in all of the studies. The GGG-
GRGDY peptide was synthesized at the University of Michi-
gan Protein and Carbohydrate Structure Core facility. Using
previously described carbodiimide chemistry,18 the carbox-
ylic acids within high M- and high G-containing alginates
were modified with GGGGRGDY peptide sequences con-
taining the RGD amino acid sequence capable of mimicking
the cell adhesion functionality of human fibronectin.24 All
reactions were performed in 0.1M MES buffer containing
0.3M NaCl at pH 6.5 with an alginate concentration of 1%
(w/v). EDC was added to the alginate to activate the car-
boxylic acids along the polymer chain at a 1:20 molar ratio to
the uronic acid monomers of the alginate. Sulfo-NHS (Pierce
Chemical) was added as a coreactant at a 1:2 molar ratio to
EDC.18 Peptide was added to the reaction, and the alginates
were allowed to react for 20 h. The modified alginates were
purified with extensive dialysis over 3 days. After dialysis,
0.5 g of activated carbon was added for every 1 gram algi-
nate and removed via filtration to further purify the mate-
rial. Peptide incorporation was quantified using 125I-labeled
GGGGRGDY as a tracer, and the peptide was custom iodin-
ated on the C-terminal tyrosine residue by Biomedical Tech-
nologies, Inc. (Stoughton, MA). The RGD-ligand density
presented at the surface of the alginate hydrogel substrates
was calculated, with the assumption that a cell had access to
the peptide in the top 5 nm of the hydrogel surface.
Material processing
RGD-modified alginates were processed into culture sur-
faces by casting alginate gels between glass plates and
punching out hydrogel disks. The alginates were dissolved
(2% w/v) in a solution with 8 g/L NaCl and 4 g/L (NaPO4)6.
The solution was sterilized by diluting the alginate to 1%
with diH2O, sterile filtration, and sterile lyophilization to
concentrate the alginate to 2%. A dual syringe method was
used to mix 1 part of 21 g/L (v/v) CaSO4 in water with
25 parts 2% alginate. The gelling alginate solution was dis-
pensed between parallel glass plates with 0.75-mm spacers,
the alginate was allowed to gel for 30–45 min, and circular
gel disks were cut out with 12.8-mm hole punches. The al-
ginate disks were equilibrated in DMEM overnight before
cell experiments.
Quantifying cell adhesion and proliferation
C2C12 mouse skeletal myoblasts (ATCC) were main-
tained in growth medium consisting of DMEM with peni-
cillin/streptomysin (10 units/L) antibiotic and supple-
mented with 10% FBS (all from Gibco, Gaithersburg, MD).
The myoblasts were maintained in subconfluent cultures at
all times before experiments, and media were changed daily
to prevent myoblast differentiation and fusion. For prolif-
eration experiments, myoblasts were seeded at approxi-
mately 2400 cells/cm2 onto alginate disks in 24-well plates.
The alginate disks were harvested over time and placed in
1 mL of 0.25M trypsin for 5 min to which 9 mL of 50 mM
EDTA in PBS (pH 7.4) was added for 20 min to dissolve the




Myoblasts were induced to differentiate by culturing in
low serum medium with supplements as established else-
where.22 The differentiation medium consisted of DMEM
with penicillin/streptomysin (10 units/L) and supple-
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mented with dexamethasone (10−7 M, Sigma), ITS (insulin,
5 mg/mL; transferrin, 5 mg/mL; sodium selenite, 5 ng/mL;
Boehringer Mannheim), and 0.5% FBS. The myoblasts were
seeded to confluence at approximately 80,000 cells/cm2, and
medium was changed daily. Myoblast differentiation was
measured qualitatively by cell fusion into multinucleated
myofibrils and quantitatively by measuring the activity of
muscle creatine kinase, an enzyme not expressed in the pro-
liferative phenotype of myoblasts and upregulated during
myoblast differentiation.23 Cell protein was collected using
passive lysis buffer (Promega, Madison, WI), which is for-
mulated to maintain enzymatic activity of cell protein. Cre-
atine kinase activity was quantified using a colorimetric




Alginates of varying M:G ratio were covalently
modified with RGD-containing peptides to obtain
model hydrogel substrates with cell-binding specific-
ity. Radioactively labeled RGD was incorporated onto
both high M and high G alginates with nearly identi-
cal incorporation efficiencies of between 55% and 60%
(Fig. 1). Less than 0.5% of the RGD remained in the
alginate after dialysis in negative control reactions
containing no EDC.
Specificity of cell adhesion
Integrin-specific adhesion to these materials was dem-
onstrated with the addition of soluble GGGGRGDY
ligand to the seeding medium. Soluble GGGGRGDY
inhibited cell spreading, and all of the cells were
round and nonadherent. Quantification of cell adhe-
sion at 4 h demonstrated that the soluble RGD blocked
cell adhesion in a dose-dependent manner (Fig. 2).
Addition of the nonadhesive peptide sequence
GGGGRGEY (varying by only one −CH2 group from
the RGD peptide) to the culture medium had no mor-
phological or adhesion blocking effects on the cells
even at the highest peptide concentration (not shown).
Varying alginate M:G ratio at a constant
ligand density
C2C12 skeletal myoblasts were seeded onto the
modified alginates (RGD densities of approximately
10 fmol/cm2) to test if cell proliferation would be
regulated by the M:G ratio of the alginate. C2C12
myoblasts express RGD-specific integrin receptors
(e.g., a5b125), and integrin-specific interactions with
these materials was expected. Myoblast adhesion at
4 h was consistent between the adhesion substrates of
varying conditions. The rate of proliferation signifi-
cantly increased as the G-content of the alginate in-
creased [Fig. 3(A)], even though the type and density
of the adhesion ligand remained constant.
The differentiation of myoblasts was next studied to
determine if this aspect of cell function would also be
dependent on alginate polymer type. The initial seed-
ing density was quantified and was the same on all
alginate types. The highest G-content substrates pro-
moted extensive fusion of the myoblasts by day 3
[Fig. 3(B)], with subsequently increasing levels of
muscle creatine kinase activity over time [Fig. 3(C)],
Figure 1. Alginates high in mannuronic acid (MVM, □ )
or guluronic acid (MVG, s) were modified with the
GGGGRGDY peptide with near identical efficiencies over
a physiologically relevant range of peptide densities. Values
reported are the average and standard deviation with an
n = 3, and the error bars are smaller than the symbols used.
Less then 0.5% of uncoupled peptide remained in the algi-
nate after purification.
Figure 2. Myoblast adhesion to alginate hydrogels modi-
fied with the GGGGRGDY peptides (4 h postseeding)
was specific to the coupled peptide, because soluble
GGGGRGDY added to the seeding medium inhibits adhe-
sion and spreading of the myoblasts. This inhibition occurs
in a dose-dependent manner as adhesion blocking experi-
ments performed in DMEM containing varying concentra-
tions of the GGGGRGDY peptide demonstrated.
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which is consistent with in vitro myogenesis on tissue
culture polystyrene substrates.22,23 However, the
lower G-content adhesion substrates (MVM and 50:50
mixture of M:G alginates) supported little to no fusion
over time [Fig. 3(B)]. Many of the myoblasts in the
nonfused cultures tended to lose adhesivity to the sub-
strate, and the cultures were a mixture of spread cells,
rounded cells, and aggregated cell clumps [Fig. 3(B)].
The creatine kinase activity was significantly lower in
these cultures [Fig. 3(C)].
Figure 3. The proliferation and differentiation were controlled by the monomeric ratio of the alginate substrates (myoblasts
were cultured on alginates of varying M:G with a constant RGD-ligand density of 10 fmol/cm2). (A) Increasing G-content at
a constant RGD density led to an increased rate of myoblast proliferation. Myoblasts on MVG (s) proliferate faster than on
MVM (d) and M:G (50:50 mix of MVG and MVM) (m). * represents statistically significant differences (p < 0.05) in cell counts
between conditions. (B) The differentiation of the myoblasts was also highly dependent on the M:G ratio. Initial myoblast
seeding densities were consistent between condition, as confirmed with cell counts. The myoblasts readily fused when on the
high-G substrates by 65 h postseeding, whereas the lower-G substrates did not support fusion. The myoblasts on the high-G
alginates at 110 h were highly fused, whereas the two low-G substrates had many rounded cells and multicellular aggregates
on the surface, with little fusion. (C) Muscle creatine kinase activity indicated that myoblast differentiation increased over
time in the cultures, and was highest on MVG (d) substrates. MVM (l) and M:G (j) substrates did not support myoblast
fusion or extensive creatine kinase activity. *Statistically significant differences (p < 0.05) in creatine kinase activity between
the highest modulus and the two low modulus conditions. [Color figure can be viewed in the online issue, which is available
at www.interscience.wiley.com.]
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Varying ligand density on high G substrates
We next altered the density of adhesion ligands
from 1 to 100 fmol/cm2 on the alginate substrates to
determine whether the adhesiveness of the biomateri-
al would modulate cell phenotype. Stiff substrates
with the lowest RGD peptide density (1 fmol/cm2)
promoted adhesion and spreading of the myoblasts
in a bipolar manner, but the cells retained an rounded
morphology. On these hydrogels, the myoblasts grew
slowly and formed aggregated cell clusters over
time. In contrast, as the RGD density increased to
10 fmol/cm2, the myoblasts were observed to spread
to an increasing extent, and the rate of myoblast pro-
liferation increased with increasing ligand density
[Fig. 4(A)]. The rate of proliferation reached a maxi-
mum at the 30 fmol/cm2 density [Fig. 4(A)], and fur-
ther increases in the RGD density did not increase the
rate of proliferation. Interestingly, raising the ligand
density from 10 to 100 fmol/cm2 on the MVM sub-
strates had little to no effect on the rate of myoblast
proliferation (data not shown).
The peptide density also modulated myoblast dif-
ferentiation and fusion. On the MVG alginate sub-
strates at low ligand densities (1 fmol/cm2), myoblasts
formed aggregated clusters and differentiated poorly
[Fig. 4(B)]. The inability of the myoblasts to fuse at the
low RGD densities resulted in low and inconsistent
creatine kinase activity [Fig. 4(C)]. Myoblasts cultured
at the intermediate ligand density (10 fmol/cm2) be-
gan fusing by 24 h and were extensively fused by
day 3 [Fig. 4(B)]. Myoblast fusion was coupled with
the characteristic increase in the overall creatine ki-
nase activity [Fig. 4(C)]. The alginate with the highest
GGGGRGDY density (100 fmol/cm2) substrates also
promoted extensive fusion and increased creatine ki-
nase activity over time, although not to a significantly
greater extent than the intermediate ligand density.
The ligand density was also increased from 10 to
100 fmol/cm2 on the MVM substrates. However, this
order of magnitude increase in ligand density was still
insufficient to promote myoblast fusion.
DISCUSSION
In the current studies, a model hydrogel substrate
based on alginate polysaccharides in which one can
independently vary the alginate monomeric ratio and
the density of adhesion ligands at the material’s sur-
face has been developed. With these studies, we have
demonstrated that skeletal myoblast proliferation and
differentiation are dependent on alginate type and the
density of adhesion ligands presented at the material’s
surface. The ability to control the phenotype of myo-
blasts in contact with a biomaterial will be important
in several applications where control over specific cell
functions or tissue formation are required.
Controlling adhesion substrate chemistry
We have covalently modified and quantified the in-
corporation of RGD-containing peptides onto purified
alginates of varying monomeric ratios. Quantifying
the chemistry with 125I-labeled peptide demonstrated
that the guluronic acid and the mannuronic acid
monomers react to the same extent using EDC chem-
istry (Fig. 1). This result was expected because the two
monomers have the same reactive carboxyl groups
with different stereochemistry. Importantly, the pep-
tide type (not shown) and density (Fig. 1) may be eas-
ily altered, because these variables have been clearly
shown to alter cell phenotype.4–6,26–28 Furthermore,
there are a number of studies that demonstrate that
alginates of varying M:G ratio lead to different in vivo
responses to the hydrogels.15–17.
Myoblast phenotype is dependent on alginate type
and ligand density
The current data indicate that the alginate type and
ligand surface density of a biomaterial substrate can
direct cellular phenotype. Myoblast proliferation rates
are highly dependent on the M:G ratio [Fig. 3(A)]. This
alginate-dependent proliferation may be useful in a
number of applications, including tissue engineering,
in which one may desire to promote controlled cell-
specific expansion and tissue formation. Varying the
ligand density also altered the rate of proliferation
[Fig. 4(A)] on the high G-content alginates; however,
myoblasts did not increase proliferation with increas-
ing ligand density on the low G-content alginates.
Thus, alterations in the materials cell-binding ability
cannot compensate for an inability of specific alginates
to promote myoblast proliferation.
It is striking that with skeletal muscle cells a com-
bination of high ligand density and high-G alginates
are required to promote differentiation of the skeletal
muscle cells (Figs. 3 and 4). Increasing the ligand den-
sity on low G substrates by an order of magnitude
cannot offset the downregulation of proliferation. In
contrast to findings with other cell types, the differen-
tiation of myoblasts increased with increasing ECM
ligand densities on high G substrates. Previously, he-
patocytes were shown to increase differentiation with
decreasing adhesion ligand density,8 and endothelial
cells differentiate maximally at intermediate levels of
adhesion ligands.26 Together, these findings suggest
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the dependence of cell function on the mechanics of
the cell–biomaterial interaction may be cell-type de-
pendent, with specific ranges of responsiveness for
different cell types. Previous reports have docu-
mented that the tractional forces exerted by cells on an
adhesion substrate are also cell-type dependent,29 and
we hypothesize that the magnitude of the forces ex-
erted by specific cell types on the biomaterial may
Figure 4. Myoblast proliferation and differentiation were dependent on the RGD-ligand density present on biomaterials of
constant M:G ratio of 30:70. (A) Myoblast cell number increased over time, and the greatest proliferation was found with the
highest ligand density. The range of density on the alginate surfaces was 1 (d), 3 (m), 10 (l), and 30 (j) fmol/cm2.
*Statistically significant differences (p < 0.05) in cell counts between conditions. (B) Myoblast differentiation also increased
with the substrate ligand density. Initial myoblast seeding densities were consistent between conditions, as determined with
cell counts. The 10- and 100-fmol/cm2 GGGGRGDY cultures differentiated by 65 h, as exhibited by myoblast fusion into
multinucleated myofibrils. The 1-fmol/cm2 cultures were less differentiated, and many multicellular aggregates formed with
some fusion between aggregates. Many of the myoblasts on the low ligand density substrates pulled away from the substrates
because of the low adhesion strength of the modified alginate. Myoblasts on the 10- and 100-fmol/cm2 density substrates
were highly fused by the 110-h time point, whereas myoblasts on the low density substrates were still aggregated clusters
with little fusion. (C) Muscle creatine kinase activity in the cultures indicated that the extent of differentiation of the
1-fmol/cm2 (d) ligand density cultures were significantly lower than the 10 (l) and 100 (j) fmol/cm2 GGGGRGDY cultures,
demonstrating a ligand density dependence on the extent of myoblasts differentiation. ∗, Statistically significant differences
(p < 0.05) in creatine kinase activity between the highest modulus and the two low modulus conditions; ∗∗, the 10- and
100-fmol/cm2 conditions are statistically different (p < 0.05) from the 1-fmol/cm2 condition. [Color figure can be viewed in
the online issue, which is available at www.interscience.wiley.com.]
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dictate the relevant range of ligand density to which
the cells will respond.
These studies lead us to conclude that the material
chemistry and ligand density are important for con-
trolling the function of cells in contact with alginate
matrices. The alginate system presented here may be
readily used to present a variety of cell adhesion or
cell signaling peptides (e.g., growth factors) directly to
the biomaterial matrix,30 and these variables may be
directly translated into in vivo experiments. These con-
cepts suggest a fundamental requirement to match
biomaterial composition to an intended cell response.
Control over these variables may allow one to regulate
targeted cell proliferation and differentiation as well
as processes such as cell migration and apoptosis.5,25
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